Profile: Astellas US LLC focuses on dermatology, immunology, urology, cardiology and therapeutic areas. We supply protopic ointment, both 0.03% and 0.1% for adults, & only 0.03% for children aged 2 to 15 years, which is indicated as a second-line therapy for short-term & non-continuous chronic treatment of moderate to severe atopic dermatitis (AD) in non-immunocompromised adults & children. Our Prograf® tacrolimus capsule is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. Our AmBisome is an antifungal agent consisting of a liposomal preparation of amphotericin B that is administered by intravenous injection. It is indicated for empirical therapy for presumed fungal infection in febrile, neutropenic patients, treatment of cryptococcal meningitis in HIV-infected patients, and treatment of patients with aspergillus species, candida species and/or cryptococcus species infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.

The company was founded in 2005, has revenues of < USD 1 Million, has ~500 employees.